Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Tchou

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Journal of the American College of Surgeons|December 4, 2003
Available models for breast cancer risk assessment: how accurate are they?Julia Tchou, Monica Morrow
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigmJulia Tchou, Jose Conejo-Garcia
Human Pathology|May 6, 2014
Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer-replyJulia Tchou, Jose Conejo-Garcia
Journal of Surgical Oncology|April 26, 2007
Barriers to rehabilitation following surgery for primary breast cancerAndrea L Cheville, Julia Tchou
Annals of Surgical Oncology|August 6, 2024
ASO Author Reflections: Rationale to Routinely Retest ER, PR and HER-2/neu Receptor Status in Residual Disease After Neoadjvuant ChemotherapySoumy Gottipati, Macy Goldbach, Julia Tchou
Surgical Oncology|September 16, 2018
Overall survival is similar between women who seek care at one or more institutions after diagnosis of operable breast cancer in the communityAustin D Williams, Alycia So, Julia Tchou
Academic Radiology|May 14, 2013
Redox imaging of human breast cancer core biopsies: a preliminary investigationHe N Xu, Julia Tchou, Lin Z Li
The Journal of Surgical Research|December 17, 2021
PTGES3 is a Putative Prognostic Marker in Breast CancerAdeseye Adekeye, Divyansh Agarwal, Anupma Nayak, et al.
Journal of Surgical Oncology|February 19, 2020
Response to "Late relapse rates in patients with early-stage hormone receptor positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy"Laura Burkbauer, Macy Goldbach, Maria Pomponio, et al.
Surgical Oncology|March 11, 2019
Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experienceDaniel I Hoffman, Paul J Zhang, Julia Tchou
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Journal of the American College of Surgeons|December 4, 2003
Available models for breast cancer risk assessment: how accurate are they?Julia Tchou, Monica Morrow
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigmJulia Tchou, Jose Conejo-Garcia
Human Pathology|May 6, 2014
Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer-replyJulia Tchou, Jose Conejo-Garcia
Journal of Surgical Oncology|April 26, 2007
Barriers to rehabilitation following surgery for primary breast cancerAndrea L Cheville, Julia Tchou
Annals of Surgical Oncology|August 6, 2024
ASO Author Reflections: Rationale to Routinely Retest ER, PR and HER-2/neu Receptor Status in Residual Disease After Neoadjvuant ChemotherapySoumy Gottipati, Macy Goldbach, Julia Tchou
Surgical Oncology|September 16, 2018
Overall survival is similar between women who seek care at one or more institutions after diagnosis of operable breast cancer in the communityAustin D Williams, Alycia So, Julia Tchou
Academic Radiology|May 14, 2013
Redox imaging of human breast cancer core biopsies: a preliminary investigationHe N Xu, Julia Tchou, Lin Z Li
The Journal of Surgical Research|December 17, 2021
PTGES3 is a Putative Prognostic Marker in Breast CancerAdeseye Adekeye, Divyansh Agarwal, Anupma Nayak, et al.
Journal of Surgical Oncology|February 19, 2020
Response to "Late relapse rates in patients with early-stage hormone receptor positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy"Laura Burkbauer, Macy Goldbach, Maria Pomponio, et al.
Surgical Oncology|March 11, 2019
Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experienceDaniel I Hoffman, Paul J Zhang, Julia Tchou
Pageof 11